vTv Therapeutics Inc Market Cap ($92.76 Million)
Market Cap & Net Worth: vTv Therapeutics Inc (VTVT)
vTv Therapeutics Inc market cap. vTv Therapeutics Inc (NASDAQ:VTVT) has a market capitalization of $92.76 Million ($92.76 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19295 globally and #4453 in its home market, demonstrating a -8.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying vTv Therapeutics Inc's stock price $23.55 by its total outstanding shares 3938654 (3.94 Million). Also see vTv Therapeutics Inc (VTVT) cash conversion ratio for how efficiently the company converts equity into cash flow.
vTv Therapeutics Inc Market Cap History (2015–2026)
vTv Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $1.07 Billion to $92.76 Million (-21.06% CAGR). Check vTv Therapeutics Inc (VTVT) stock price for real-time trading data and today's change.
Index Memberships
vTv Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #540 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1850 of 3165 |
Weight: vTv Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
vTv Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how vTv Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore vTv Therapeutics Inc (VTVT) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
53.48x
vTv Therapeutics Inc's market cap is 53.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $760.95 Million | $634.00K | -$16.35 Million | 1200.23x | N/A |
| 2017 | $946.85 Million | $291.00K | -$16.14 Million | 3253.79x | N/A |
| 2018 | $417.50 Million | $12.43 Million | -$7.91 Million | 33.58x | N/A |
| 2019 | $267.83 Million | $2.76 Million | -$21.94 Million | 96.90x | N/A |
| 2020 | $293.04 Million | $6.41 Million | -$8.50 Million | 45.69x | N/A |
| 2021 | $156.76 Million | $4.00 Million | -$12.99 Million | 39.14x | N/A |
| 2022 | $104.42 Million | $2.02 Million | -$19.16 Million | 51.75x | N/A |
| 2023 | $45.29 Million | $9.00K | -$20.25 Million | 5032.72x | N/A |
| 2024 | $54.39 Million | $1.02 Million | -$18.46 Million | 53.48x | N/A |
Competitor Companies of VTVT by Market Capitalization
Companies near vTv Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see how large is vTv Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to vTv Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of vTv Therapeutics Inc (2015–2026)
Market capitalization of vTv Therapeutics Inc from 2015 to today. Between 2015 and today, vTv Therapeutics Inc's market cap moved from $1.07 Billion to $ 92.76 Million, with a yearly change of -21.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $92.76 Million | -41.11% |
| 2025 | $157.51 Million | +189.60% |
| 2024 | $54.39 Million | +20.08% |
| 2023 | $45.29 Million | -56.62% |
| 2022 | $104.42 Million | -33.39% |
| 2021 | $156.76 Million | -46.51% |
| 2020 | $293.04 Million | +9.41% |
| 2019 | $267.83 Million | -35.85% |
| 2018 | $417.50 Million | -55.91% |
| 2017 | $946.85 Million | +24.43% |
| 2016 | $760.95 Million | -29.07% |
| 2015 | $1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of vTv Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $92.76 Million USD |
| MoneyControl | $92.76 Million USD |
| MarketWatch | $92.76 Million USD |
| marketcap.company | $92.76 Million USD |
| Reuters | $92.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more